The full data for the Phase III trial of lecanemab has been published, showing that the drug slows cognitive decline but also raises safety concerns.
After positive early data was released in September 2022, the widely anticipated full data from the Phase III trial of the monoclonal antibody lecanemab was published in the New England Journal of Medicine and presented at the 15th Clinical Trials on Alzheimer’s Disease conference (29 November–2 December 2022; San Francisco, CA, USA). The findings, which show the drug slows cognitive decline in people living with Alzheimer’s disease, are cause for both optimism and caution.
[ui-btn url=”https://www.neuro-central.com/lecanemab-alzheimers-drug-is-a-cause-for-both-optimism-and-caution/” text=”READ MORE ON NEURO CENTRAL NOW” target=”_blank”][/ui-btn]
The post New Alzheimer’s drug is a cause for both optimism and caution appeared first on BioTechniques.
Full BioTechniques Article here
Powered by WPeMatico